← Leaderboards
John D Roberts
Virginia Commonwealth University
$6,720,279
Attributed
$6,720,279
Total exposure
23
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $732.2K · FY2005–11$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
Funding mix
By agency
NIH$6,720,279 · 23
By mechanism
U10$5,997,886 · 1
R21$285,335 · 1
M01$226,399 · 20
P30$210,659 · 1
Top collaborators
No co-investigators on record.
Most similar at Virginia Commonwealth University
Same institution · by research overlap
- Gordon D Ginder$21,192,432
- Wally R Smith$9,055,907
- Nolan Wages$2,368,536
- Jacqueline M Hibbert$1,404,511
- Martin K Safo$4,719,250
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchClinical TrialsResearch PersonnelHuman SubjectCancer PreventionAfrican AmericanHuman Therapy EvaluationGrantUnited States National Institutes Of HealthComputer Retrieval Of Information On Scientific Projects DatabaseHealth PersonnelGynecologic Oncology GroupMinority-Based Community Clinical Oncology ProgramCancer Trials Support UnitInstitutionFundingMalignant NeoplasmsCommunity Clinical Oncology ProgramClinical Trial Phase IControlled StudyBaseCancer And Leukemia Group BCancer TherapyControlled Clinical Trials
Grant awards (49)
VCU Minority-Based Community Clinical Oncology Program$490,679
U10 · FY2011 · CA · contact PI
VCU Minority-Based Community Clinical Oncology Program$50,000
U10 · FY2011 · CA · contact PI
VCU Minority-Based Community Clinical Oncology Program$359,518
U10 · FY2010 · CA · contact PI
VCU Minority-Based Community Clinical Oncology Program$197,549
U10 · FY2010 · CA · contact PI
VCU Minority-Based Community Clinical Oncology Program$100,001
U10 · FY2010 · CA · contact PI
Clinical Protocol and Data Management$52,741
P30 · FY2010 · CA · contact PI
CLINICAL TRIAL: COMBINED TREATMENT WITH BORTEZOMIB & DACARBAZINE$22,389
M01 · FY2010 · RR · contact PI
VCU Minority-Based CCOP$314,164
U10 · FY2009 · CA · contact PI
VCU Minority-Based CCOP$99,999
U10 · FY2009 · CA · contact PI
Clinical Protocol and Data Management$54,519
P30 · FY2009 · CA · contact PI
CLINICAL TRIAL: COMBINED TREATMENT WITH BORTEZOMIB & DACARBAZINE$32,191
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: NCI 6858: A PHASE 1 STUDY OF SUBEROYLANILIDE HYDROXAMIC ACID (S$24,259
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: A PHASE 2 STUDY OF AZD6244 IN ADVANCED OR METASTATIC HEPATOCELLU$13,996
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: PILOT/PHASE 1 STUDY OF ZOLEDRONIC ACID (ZOMETA ) IN SICKLE CELL$934
M01 · FY2009 · RR · contact PI
VCU Minority-Based CCOP$577,110
U10 · FY2008 · CA · contact PI
Clinical Protocol and Data Management$20,977
P30 · FY2008 · CA · contact PI
CLINICAL TRIAL: NCI 6858: A PHASE 1 STUDY OF SUBEROYLANILIDE HYDROXAMIC ACID (S$9,102
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: COMBINED TREATMENT WITH BORTEZOMIB & DACARBAZINE$3,792
M01 · FY2008 · RR · contact PI
VCU Minority-Based CCOP$527,332
U10 · FY2007 · CA · contact PI
VCU Minority-Based CCOP$100,000
U10 · FY2007 · CA · contact PI
NCI 6858: A PHASE 1 STUDY OF SUBEROYLANILIDE HYDROXAMIC ACID (SAHA) IN COMBI$18,962
M01 · FY2007 · RR · contact PI
COMBINED TREATMENT WITH BORTEZOMIB & DACARBAZINE$14,748
M01 · FY2007 · RR · contact PI
BONE TURNOVER IN SICKLE CELL DISEASE$5,618
M01 · FY2007 · RR · contact PI
VCU Minority-Based CCOP$505,318
U10 · FY2006 · CA · contact PI
COMBINED TREATMENT WITH BORTEZOMIB & DACARBAZINE$32,883
M01 · FY2006 · RR · contact PI
BONE TURNOVER IN SICKLE CELL DISEASE$633
M01 · FY2006 · RR · contact PI
VCU Minority-Based CCOP$444,133
U10 · FY2005 · CA
COMBINED TREATMENT WITH BORTEZOMIB &DACARBAZINE$371
M01 · FY2005 · RR
VCU MINORITY-BASED CCOP$463,063
U10 · FY2004 · CA
Modulation of the Bio. Response to IL-2 with Bryostatin$43,281
M01 · FY2004 · RR
VCU MINORITY-BASED CCOP$429,311
U10 · FY2003 · CA
VCU MINORITY-BASED CCOP$438,373
U10 · FY2002 · CA
CORE--CLINICAL PROTOCOL AND DATA MANAGEMENT$41,211
P30 · FY2002 · CA
VCU MINORITY-BASED CCOP$459,337
U10 · FY2001 · CA
PHASE 1 TRIAL OF BRYOSTATIN AND INTERLEUKIN-2$143,504
R21 · FY2001 · CA
CLINICAL STUDY OF 4BM IN SICKLE CELL DISEASE$0
M01 · FY2001 · RR
LY231514 &DOCETAXEL DOSING IN CANCER$0
M01 · FY2001 · RR
EFFECT OF DELTA 9 TETRAHYDROCANNABINOL ON MORPHINE ANALGESIA IN NORMA$0
M01 · FY2001 · RR
A PHASE I STUDY OF THE GARFT INHIBITOR AG2034 IN PATIENTS WITH ADVANCED CANCER$0
M01 · FY2001 · RR
PHASE I DOSE ESCALATION OF MULTIAGENT CHEMOTHERAPY, LEUCOVORIN/GEMZAR$0
M01 · FY2001 · RR
VCU MINORITY-BASED CCOP$441,999
U10 · FY2000 · CA
PHASE 1 TRIAL OF BRYOSTATIN AND INTERLEUKIN-2$141,831
R21 · FY2000 · CA
CORE--CLINICAL RESEARCH$41,211
P30 · FY2000 · CA
PHASE I DOSE ESCALATION OF MULTIAGENT CHEMOTHERAPY, LEUCOVORIN/GEMZAR$648
M01 · FY2000 · RR
CLINICAL STUDY OF 4BM IN SICKLE CELL DISEASE$648
M01 · FY2000 · RR
LY231514 &DOCETAXEL DOSING IN CANCER$648
M01 · FY2000 · RR
EFFECT OF DELTA 9 TETRAHYDROCANNABINOL ON MORPHINE ANALGESIA IN NORMA$648
M01 · FY2000 · RR
A PHASE I STUDY OF THE GARFT INHIBITOR AG2034 IN PATIENTS WITH ADVANCED CANCER$648
M01 · FY2000 · RR
OSTEOCLAST ACTIVATION AND INHIBITION IN SICKLE CELL$0
M01 · FY2000 · RR